RxDoctor Payments Data

Maria Nash, MD

Family Medicine · Huntington, WVNPI 1881956506

Payments from drug & device makers

$4,642in general payments, 2019–2025

Across 305 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$676
  • Lilly USA, LLC$495
  • Novo Nordisk$365
  • Pfizer$344
  • AstraZeneca$267
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$4,625100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,642 in reported general payments places this provider in the 85th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$12,518
Medicare patients
100
Services billed
155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$74,705
EliquisApixaban86$73,514
JardianceEmpagliflozin55$67,918
MounjaroTirzepatide35$42,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$38,818
JanuviaSitagliptin Phosphate35$36,154
RybelsusSemaglutide16$31,572
TrulicityDulaglutide26$26,749
LinzessLinaclotide26$24,425
FarxigaDapagliflozin Propanediol22$24,396
Breo ElliptaFluticasone/Vilanterol28$19,703
XareltoRivaroxaban12$19,475
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$13,916
TradjentaLinagliptin17$11,880
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$10,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$365$106,27771 claims
Boehringer IngelheimJardiance, Tradjenta$67$79,79872 claims
PfizerEliquis$344$73,51486 claims
Lilly USA, LLCMounjaro, Trulicity$495$69,16561 claims
GSKTrelegy Ellipta, Breo Ellipta$1,057$58,52064 claims
MerckJanuvia$214$36,15435 claims
AbbVieLinzess, Synthroid$676$25,43455 claims
AstraZenecaFarxiga$267$24,39622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →